The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Cetuximab, capecitabine, oxaliplatin, and radiotherapy as preoperative triple treatment for rectal cancer (CET-CAPOX-RT-Phase-I/II Study): Influence on long-term survival and relevance of biomarkers.
Torsten Liersch
No relevant relationships to disclose
Lena-Christin Conradi
No relevant relationships to disclose
Thilo Sprenger
No relevant relationships to disclose
Peter Middel
No relevant relationships to disclose
Heiko Sülberg
No relevant relationships to disclose
Franz Rödel
No relevant relationships to disclose
Josef Rüschoff
No relevant relationships to disclose
Tim Beissbarth
No relevant relationships to disclose
Dirk Arnold
No relevant relationships to disclose
Claus Rödel
No relevant relationships to disclose